CancerVax About
CanceVax CancerVax
Corporation is a biotechnology company focused on the research, development, and
commercialization of biological products for the treatment and control of cancer.
CancerVax's lead product candidate is CanvaxinTM, one of a new class
of products being developed in the area of specific active immunotherapy, also
known as therapeutic cancer vaccines. In
addition to Canvaxin™, CancerVax has licensed three specific active immunotherapeutic
product candidates targeting EGFR. The Company plans to identify and develop new
product candidates based on specific active immunotherapy, anti-angiogenesis and
T-oligonucleotide, or telomere homolog oligonucleotide, technology platforms.
More on CancerVax